Evaluating the Long‐Term Benefits of Medications for Alcohol Use Disorder in Alcohol‐Associated Cirrhosis
This study demonstrates the significant benefits of MAUD in patients with alcohol-associated cirrhosis, including reduced mortality, lower healthcare utilisation and improved alcohol abstinence rates, supporting its integration into standard care protocols.
Authors
- Nagesh Jadhav (ORCID: https://orcid.org/0000-0001-8993-3947)
- Kaiwen Zhu (ORCID: https://orcid.org/0000-0002-1734-2512)
- Utsav Joshi (ORCID: https://orcid.org/0000-0002-8251-5846)
- Patrick Okolo (ORCID: https://orcid.org/0000-0003-0928-7303)
- Ebubekir Daglilar (ORCID: https://orcid.org/0000-0003-0622-1704)
- Aditya Sanjeevi (ORCID: https://orcid.org/0000-0001-8899-633X)
- Jing Zhang (ORCID: https://orcid.org/0000-0001-5901-5969)
- Akshatha Rao (ORCID: https://orcid.org/0000-0001-7492-460X)
- Daniel‐Jose Idoate‐Domench
Institutions
- Charleston Area Medical Center (US)
- Vancouver Hospital and Health Sciences Centre (CA)
- Moffitt Cancer Center (US)
- Rochester General Hospital (US)
- Carilion Clinic (US)
Publication Details
- Journal
- Liver International
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1111/liv.70424
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00